DraxImage to bring generic sestamibi to market

Feb 1, 2007

Canadian radiopharmaceutical firm DraxImage has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for its generic kit for the preparation of technetium-99m (Tc-99m) sestamibi.

Tc-99m sestamibi is a nuclear medicine imaging agent used in myocardial perfusion imaging (MPI). Once its ANDA is approved, the Kirkland, Quebec-based developer said it plans to enter the MPI market after the key patent for the currently marketed Tc-99m sestamibi product expires, which is expected to be in 2008 for the U.S. The firm said it also plans to file for marketing approvals in other jurisdictions, including European countries.

Tc-99m sestamibi is currently marketed under the trade name Cardiolite by Bristol-Myers Squibb Medical Imaging of North Billerica, MA.

By AuntMinnie.com staff writers
February 2, 2007

Draxis reports income, revenue gains in Q2, August 10, 2006

Draxis joins Nasdaq Global Select Market, July 5, 2006

Draxis posts Q1 downturn, May 11, 2006

DraxImage shelves Fibrimage, unveils new generics initiative, March 28, 2006

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$